As can be seen in that table, the median age of the patients was similar in all cohorts, although the number of patients with a previous history of hormonal therapy and chemotherapy, as well as Xofigo® (Ra-223) therapy, was clearly higher in patients with mCRPC than in patients with primary PCa and HS-BCR PCa. The gene discussed is BCR; the disease is posterior cortical atrophy.